Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06629402 · ClinicalTrials.gov registry record · Phase 2
Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)
A Phase 2 study of Acute Pain, sponsored by Ensysce Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06629402: Completed Phase 2 study of Acute Pain, sponsored by Ensysce Biosciences.
NCT06629402 is a Phase 2 study of Acute Pain that has completed, run by Ensysce Biosciences. The registered enrollment target is 16 participants, below the 268-participant average among 50 other Acute Pain trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06629402, a Phase 2 study of Acute Pain, has completed, sponsored by Ensysce Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to evaluate the onset of analgesia following administration of a single oral dose of PF614 (50 mg or 100 mg) or placebo in healthy male subjects in an experimental pain model (cold pressor test \[CPT\]).
Primary Outcome
The time to first pain was recorded by trained site staff using a stop watch. Each subject was instructed to remove their hand at 3 minutes if they had not yet reached pain tolerance. Separate assessments were made at pre-dose (within 60 minutes prior to dosing; at least duplicate measurements, 30 minutes apart) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hours post-dose.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF614
Study Locations (1)
Kansas
- Dr. Vince Clinical Research - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-10-05 |
| Est. Completion | 2023-11-15 |
| Phase | Phase 2 |
What the finished NCT06629402 record still lists
NCT06629402 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 268-participant average among 50 other Acute Pain trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06629402 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT06629402 about?
NCT06629402 is a clinical study titled "Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)". The primary objective of the study is to evaluate the onset of analgesia following administration of a single oral dose of PF614 (50 mg or 100 mg) or placebo in healthy male subjects in an experimental pain model (cold pressor test \[CPT\]).
What is the current status of trial NCT06629402?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2023-10-05. Estimated completion is 2023-11-15.
What conditions does trial NCT06629402 study?
This clinical trial studies the following conditions: Acute Pain.
What interventions are being tested in trial NCT06629402?
The interventions under investigation include: Placebo (DRUG), PF614 (DRUG).
Who is sponsoring clinical trial NCT06629402?
This trial is sponsored by Ensysce Biosciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06629402 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06629402's enrollment target sits among peer trials
16 51st of 50 the lowest of 50 other Acute Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reducing Pain From Wisdom Molar Extractions
RECRUITING · Phase 2
-
Twin Block, Pain Medications and Third Molar Extractions
RECRUITING · Phase 2
-
Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain
COMPLETED · Phase 2
-
Liposome Bupivacaine Interscalene Total Shoulder
COMPLETED · Phase 2
-
Acetaminophen Versus IV Hydromorphone for Pain in the Elderly in the ED
COMPLETED · Phase 2
-
A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI